Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
Publication year
2011Source
Antimicrobial Agents and Chemotherapy, 55, 3, (2011), pp. 1287-1289ISSN
Annotation
1 maart 2011
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Pulmonary Diseases
Medical Microbiology
Journal title
Antimicrobial Agents and Chemotherapy
Volume
vol. 55
Issue
iss. 3
Page start
p. 1287
Page end
p. 1289
Subject
N4i 1: Pathogenesis and modulation of inflammation; N4i 1: Pathogenesis and modulation of inflammation NCMLS 1: Infection and autoimmunity; N4i 3: Poverty-related infectious diseasesAbstract
Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).
This item appears in the following Collection(s)
- Academic publications [203812]
- Faculty of Medical Sciences [80326]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.